AstraZeneca PLC‘s AZN solid third-quarter results, along with a shift in the clinical trial results for a lung cancer drug candidate, "remove overhangs," according to RBC Capital Markets analyst Trung ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Share forecast & analyst price target predictions based on 16 analysts offering 12-month price targets for AZN in the last 3 months.

AstraZenecaâ s (LSE: AZN) share price looks to me to be anchored to an outdated view of its long-term earnings potential. This appears to reflect a mature, late-cycle pharmaceutical firm reliant on a ...

AstraZeneca PLC (AZN), the Cambridge, United Kingdom-headquartered Pharma giant with a market cap valuation just shy of $300bn at the time of writing (source: TradingView), announced its Q4 and ...

LONDON, July 24 (Reuters) - ⁠AstraZeneca's ⁠long-time CEO Pascal Soriot has rarely put a ⁠foot wrong. The company's shares have more that quadrupled in price during his 14-year tenure, soaring above ...

AstraZeneca's share price jumped 4% in early trading on Friday ...

AstraZeneca plc is in focus after a series of recent US drug approvals, a $155 million milestone payment to Daiichi Sankyo and a director share award for CEO Pascal Soriot. What these headlines reveal ...